Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $105,600.00 in Stock

Key Points

• Director Blake Borgeson sold 30,000 shares at an average price of $3.52 for $105,600 under a pre‑arranged Rule 10b5‑1 plan, a disclosed transaction that trimmed his stake by about 0.48% and appears routine.
• Q1 results showed an EPS beat but a material revenue miss — loss per share of $0.22 vs. consensus ‑$0.30, while revenue fell to $6.47M vs. ~$15.8M expected (‑56.8% y/y), leaving the company with negative margins and analysts expecting continued losses.
• Management highlighted tangible clinical progress (notably REC‑1245 early data described as well‑tolerated), but analyst sentiment is mixed with a consensus "Hold" and a $9.20 target amid several downgraded price targets and ratings.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 30,000 shares of the business's stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $3.52, for a total value of $105,600.00. Following the sale, the director owned 6,199,863 shares of the company's stock, valued at approximately $21,823,517.76. This represents a 0.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, April 7th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.10, for a total value of $93,000.00.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ:RXRX traded down $0.16 during trading on Thursday, reaching $3.27. 11,967,164 shares of the stock were exchanged, compared to its average volume of 16,680,465. Recursion Pharmaceuticals, Inc. has a 12 month low of $2.80 and a 12 month high of $7.18. The firm has a market cap of $1.72 billion, a PE ratio of -2.21 and a beta of 1.05. The stock has a 50-day moving average price of $3.40 and a 200-day moving average price of $4.13. The company has a current ratio of 5.50, a quick ratio of 5.50 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative return on equity of 63.98% and a negative net margin of 863.37%.The company had revenue of $6.47 million during the quarter, compared to analysts' expectations of $15.78 million. During the same quarter in the previous year, the company posted ($0.50) earnings per share. The business's revenue was down 56.8% on a year-over-year basis. Research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.08 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on RXRX shares. Wall Street Zen cut Recursion Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, March 28th. Needham & Company LLC restated a "buy" rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday. JPMorgan Chase & Co. lowered their price objective on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an "overweight" rating for the company in a research report on Thursday, April 30th. Bank of America lowered their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "neutral" rating for the company in a report on Wednesday, February 25th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $9.20.

Key Stories Impacting Recursion Pharmaceuticals

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: Management highlighted tangible clinical progress across wholly‑owned and partnered programs (REC‑1245, REC‑4881, REC‑4539), including early REC‑1245 safety/PK data and FDA engagement on REC‑4881 — items that support long‑term value creation. Press Release
• Positive Sentiment: Early clinical data for RBM39 degrader REC‑1245 were described as well‑tolerated with dose‑dependent PK and no DLTs to date — an encouraging Phase 1/2 signal that analysts and biotech investors typically reward. Yahoo AI Stock Article
• Positive Sentiment: Analyst support: Needham reaffirmed a Buy and set an $8 price target, implying substantial upside from current levels and providing a catalyst if broader sentiment improves. Benzinga
• Neutral Sentiment: Q1 results and the earnings/strategy call emphasized “signal over noise” and prioritizing proof‑points from AI‑driven programs — a message that supports thesis execution but is not an immediate financial catalyst. Earnings Transcript
• Neutral Sentiment: Insider transaction: Director Blake Borgeson sold 30,000 shares under a pre‑arranged Rule 10b5‑1 plan (small ~0.48% reduction in his holdings), a routine disclosure that appears procedural rather than a red flag. Insider Trades
• Negative Sentiment: Revenue missed expectations materially — Q1 revenue of $6.47M versus ~$15.8M expected, down ~57% year‑over‑year as Roche collaboration income declined; this top‑line deterioration is the primary near‑term driver of the share pullback. MarketBeat Earnings
• Negative Sentiment: Despite an EPS beat (loss of $0.22 vs. consensus ‑$0.30), the company still shows negative margins and returns, and analysts expect continued losses — meaning valuation depends heavily on future trial readouts and partnership revenue recovery. Zacks

Institutional Trading of Recursion Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Xponance Inc. boosted its position in Recursion Pharmaceuticals by 8.0% during the third quarter. Xponance Inc. now owns 30,020 shares of the company's stock valued at $146,000 after acquiring an additional 2,221 shares during the last quarter. NewEdge Advisors LLC boosted its position in Recursion Pharmaceuticals by 28.1% during the second quarter. NewEdge Advisors LLC now owns 11,061 shares of the company's stock valued at $56,000 after acquiring an additional 2,428 shares during the last quarter. Equitable Holdings Inc. boosted its position in Recursion Pharmaceuticals by 7.1% during the third quarter. Equitable Holdings Inc. now owns 39,400 shares of the company's stock valued at $192,000 after acquiring an additional 2,600 shares during the last quarter. Cherry Creek Investment Advisors Inc. boosted its position in Recursion Pharmaceuticals by 4.1% during the third quarter. Cherry Creek Investment Advisors Inc. now owns 66,781 shares of the company's stock valued at $326,000 after acquiring an additional 2,649 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its position in Recursion Pharmaceuticals by 1.2% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 232,370 shares of the company's stock valued at $954,000 after acquiring an additional 2,753 shares during the last quarter. Institutional investors own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc NASDAQ: RXRX is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.